Atara Biotherapeutics Faces Securities Fraud Lawsuit Over Alleged Misleading Statements
Atara Biotherapeutics, Inc. (ATRA) is facing a securities fraud class action lawsuit, with allegations that the company failed to disclose manufacturing issues and deficiencies in its ALLELE study, which may have misled investors. The lawsuit claims these issues negatively impacted the company's regulatory prospects and financial condition. Investors who suffered losses are being urged to contact the Law Offices of Howard G. Smith before May 22, 2026.
Tickers: $ATRA
Topics: class action FDA approval lawsuit regulatory issues securities fraud